Raising full-year 2026 sales growth guidance to 9-11%
Edwards Lifesciences reported a strong Q1 FY2026 with total sales up 12.7%, beating expectations. The company raised its full-year guidance across total sales, TAVR, and EPS. TAVR growth benefited from clinical evidence and a competitor exit in Europe, while TMTT grew 42% driven by new products like Evoque, Pascal, and Sapien M3. Total Q1 sales $1.65B, +12.7% y/y, above guidance; adjusted EPS $0.78.
Вывод BuzzbergRaising full-year 2026 sales growth guidance to 9-11%Edwards Lifesciences reported a strong Q1 FY2026 with total sales up 12.7%, beating expectations. The company raised its full-year guidance across total sales, TAVR, and EPS. TAVR growth benefited from clinical evidence and a competitor exit in Europe, while TMTT grew 42% driven by new products like Evoque, Pascal, and Sapien M3. Total Q1 sales $1.65B, +12.7% y/y, above guidance; adjusted EPS $0.78.Читать полный анализСвернуть анализ
Edwards Lifesciences reported a strong Q1 FY2026 with total sales up 12.7%, beating expectations. The company raised its full-year guidance across total sales, TAVR, and EPS. TAVR growth benefited from clinical evidence and a competitor exit in Europe, while TMTT grew 42% driven by new products like Evoque, Pascal, and Sapien M3. Total Q1 sales $1.65B, +12.7% y/y, above guidance; adjusted EPS $0.78.
TAVR sales $1.2B (+11%), raised full-year guidance to 7-9% growth.
TMTT sales $173M (+42%), strong adoption of Evoque, Pascal, and Sapien M3; on track for $740-780M full year.
Surgical sales $276M (+6%), mid-single-digit growth expected for 2026.
SURGICAL revenue$0.276B
reported
TAVR revenue$1.2B
reported
TMTT revenue$0.173B
reported
Revenue$1.6486B
+5% QoQ
Что изменилось в этом квартале
01
Guidance
Raising full-year 2026 sales growth guidance to 9-11%
Guidance · revenue to $6.7B
02
Guidance
TAVR full-year guidance raised to 7-9% growth
Guidance · revenue to $6.7B
03
TMTT
TMTT targeting $2 billion revenue in 2030
TAVR sales $1.2B (+11%), raised full-year guidance to 7-9% growth.
04
Pipeline
Progress trial results to be presented at TCT
TMTT sales $173M (+42%), strong adoption of Evoque, Pascal, and Sapien M3; on track for $740-780M full year.
Спрос и капзатраты
Спрос
Заказы и конверсия
Management raised full-year guidance across total company, TAVR, and EPS, citing strong Q1 momentum and broad-based growth, signaling improving confidence in the durable multi-year growth trajectory.
Капзатраты
Инвестиции и мощности
Management discussed ongoing strategic investments in clinical evidence generation, technology advancements, and resources to support patient care, but did not provide specific capex guidance. They expect operating margin expansion in 2027 and beyond, indicating disciplined investment spending.
Тон · Confident
Management expressed confidence in their differentiated strategy and raised full-year guidance, citing strong Q1 performance and positive clinical data momentum.
Альфа цепочки поставок
A1
A competitor exited the European TAVR market, providing a slight year-over-year share gain for Edwards in Q1.
“Edouard's global competitive position in the first quarter increased slightly year over year, mainly due to the exit of a competitor in Europe.”